Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

PD-L1 IHC 22C3 pharmDx is a companion diagnostic used to Recalled by Dako North America Inc. Due to To correct the kit's instructions for use as...

Date: February 2, 2018
Company: Dako North America Inc.
Status: Terminated
Source: FDA (Device)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Dako North America Inc. directly.

Affected Products

PD-L1 IHC 22C3 pharmDx is a companion diagnostic used to determine PD-L1 levels for determination of patient treatment options.

Quantity: 1051 kits

Why Was This Recalled?

To correct the kit's instructions for use as the storage time for gastric and gastroesophageal junction adenocarcinoma cut sections will be changed from six months to five months.

Where Was This Sold?

This product was distributed to 29 states: AZ, CA, CO, CT, FL, GA, IL, IN, KS, KY, LA, ME, MD, MA, MI, MO, NV, NH, NJ, NY, OH, OK, PA, TX, UT, VA, WA, WI, DC

Affected (29 states)Not affected

About Dako North America Inc.

Dako North America Inc. has 8 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Device). Last updated March 26, 2026. View original report